Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer

Anaplastic lymphoma kinase (ALK) gene rearrangement counts for approximately 5 % –7 % of non-small cell lung cancer (NSCLC) [1]. This kind of fusion represents a distinct mechanism of driver mutation in NSCLC. More than 19 different fusion partners have been identified in cancer patients [2]. The fusion of echinoderm microtubule-associated protein like 4 (EML4) and ALK is the most common fusion pattern, which occurred in at least 80 % ALK positive lung cancers [3,4].

Source: Lung Cancer - September 23, 2020 Category: Cancer & Oncology Authors: Hong Tao, Liang Shi, Aoxue Zhou, Hongxia Li, Fei Gai, Zhan Huang, Nanying Che, Zhe Liu Source Type: research